Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 4.9: Experimentelle Antiangiogenesetherapie

Autor/en: C.D. Mnich, R. Dummer
Letzte Änderung: 01.12.2006
  • Alatrash G et al.
    Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    J Clin Oncol 2004;22:2891-2900.


  • Bartlett JB et al.
    Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
    Br J Cancer 2004;90:955-961.


  • Bauer JA et al.
    IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
    J Interferon Cytokine Res 2003;23:3-10.


  • Bhargava P et al.
    A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Clin Cancer Res 1999;5:1989-1995.


  • Bond SJ et al.
    Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors.
    J Surg Res 2000;92:18-22.


  • Bramhall SR et al.
    Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
    J Clin Oncol 2001;19:3447-3455.


  • Buerkle MA et al.
    Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.
    Br J Cancer 2002;86:788-795.


  • Dabrowska A et al.
    Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
    Neoplasma 2001;48:358-361.


  • Detmar M et al.
    Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.
    Am J Pathol 2000;156:159-167.


  • Dezube BJ et al.
    Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
    J Clin Oncol 1998;16:1444-1449.


  • Dhanabal M et al.
    Cloning, expression, and in vitro activity of human endostatin.
    Biochem Biophys Res Commun 1999;258:345-352.


  • Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA.
    Thalidomide in cancer medicine.
    Ann Oncol 2004;15:1151-1160.


  • Feldman AL et al.
    Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.
    Cancer Res 2000;60:1503-1506.


  • Fernando NH, Hurwitz HI.
    Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
    Semin Oncol 2003;30(3 Suppl 6):39-50.


  • Gray R et al.
    The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF).
    Proc Am Soc Clin Oncol 2003;22:206.


  • Heinzerling LM et al.
    Intratumoral injection of DNA encoding human interleukin-12 in metastatic melanoma patients with local and some systemic response.
    Hum Gene Ther 2005;16:35-48.


  • Heinzerling LM et al.
    Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice.
    Exp Dermatol 2002;11:232-240.


  • Heinzerling LM et al.
    Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses.
    J Mol Med 2001;78:692-702.


  • Hinoda Y et al.
    Monoclonal antibodies as effective therapeutic agents for solid tumors.
    Cancer Sci 2004;95:621-625.


  • Hwu WJ et al.
    Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    J Clin Oncol 2003;21:3351-3356.


  • Hwu WJ.
    New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
    Oncology 2000;14:25-28.


  • Itoh T et al.
    Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
    Cancer Res 1998;58:1048-1051.


  • Johnson DH et al.
    Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
    J Clin Oncol 2004;22:2184-2191.


  • Kim YM et al.
    Endostatin inhibits endothelialvand tumor cellular invasion by blockingvthe activation and catalytic activity ofvmatrix metalloproteinase.
    Cancer Res 2000;60:5410-5413.


  • Kirkwood JM et al.
    High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/ C9190.
    J Clin Oncol 2000;18:2444-2458.


  • Krown SE.
    Management of Kaposi sarcoma: the role of interferon and thalidomide.
    Curr Opin Oncol 2001;13:374-381.


  • Kruger A et al.
    Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
    Cancer Res 2001;61:1272-1275.


  • Kuenen BC et al.
    Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Clin Cancer Res 2003;9:1648-1655.


  • Kurzen H et al.
    Inhibition of angiogenesis by non-toxic doses of temozolomide.
    Anticancer Drugs 2003;14:515-522.


  • Lacal PM et al.
    Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.
    J Invest Dermatol 2000;115:1000-1007.


  • Laffitte E, Revuz J.
    Thalidomide: an old drug with new clinical applications.
    Expert Opin Drug Saf 2004;3:47-56.


  • Laird AD et al.
    SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Cancer Res 2000;60:4152-4160.


  • Lee HM et al.
    CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.
    Curr Med Chem 2001;8:257-260.


  • Lindner DJ, Interferons as antiangiogenic agents.
    Curr Oncol Rep 2002;4:510-514.


  • Lucas ML, Heller R.
    IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
    DNA Cell Biol 2003;22:755-763.


  • Lukkonen A et al.
    Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration.
    Int J Cancer 2000;86:577-581.


  • Luttun A, Carmeliet P.
    Angiogenesis and lymphangiogenesis: highlights of the past year.
    Curr Opin Hematol 2004;11:262-271.


  • Maniotis AJ et al.
    Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
    Am J Pathol 1999;155:739-752.


  • Marchetti D et al.
    Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
    Int J Cancer 2003;104:167-174.


  • Mendel DB et al.
    Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent.
    Anticancer Drug Des 2000;15:29-41.


  • Miller KD.
    Issues and challenges for antiangiogenic therapies.
    Breast Cancer Res Treat 2002;75 Suppl 1:45-50;discussion:57-58.


  • Mitjans F et al.
    In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
    Int J Cancer 2000;87:716-723.


  • Motzer RJ et al.
    Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
    J Clin Oncol 2002;20:289-296.


  • Nelson AR et al.
    Matrix metalloproteinases: biologic activity and clinical implications.
    J Clin Oncol 2000;18:1135-1149.


  • Niethammer AG et al.
    A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.
    Nat Med 2002;8:1369-1375.


  • Parker V, Sandberg J, Smith J.
    Phase I and pharmacokinetic studies of angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1.
    Proc Am Soc Clin Oncol 2000;19:703.


  • Patel SR et al.
    Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas.
    Cancer 2001;92:1347-1348.


  • Pavco PA et al.
    Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
    Clin Cancer Res 2000;6:2094-2103.


  • Pawlak WZ.
    Legha SS, Phase II study of thalidomide in patients with metastatic melanoma.
    Melanoma Res 2004;14:57-62.


  • Posey JA et al.
    A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.
    Cancer Biother Radiopharm 2001;16:125-132.


  • Quirt I et al.
    Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
    Invest New Drugs 2002;20:431-437.


  • Reijneveld JC et al.
    Angiostatin prolongs the survival of mice with leptomeningeal metastases.
    Eur J Clin Invest 2003;33:76-81.


  • Ridolfi R et al.
    Temozolomide and interferonalpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
    Melanoma Res 2004;14:295-299.


  • Rodolfo M et al.
    Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy.
    Cancer Gene Ther 2001;8:491-496.


  • Rofstad EK, Halsor EF.
    Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Cancer Res 2000;60:4932-4938.


  • Saltz LB et al.
    Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    N Engl J Med 2000;343:905-914.


  • Sandberg JA et al.
    Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.
    Antisense Nucleic Acid Drug Dev 2000;10:153-162.


  • Stadler WM et al.
    Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
    J Clin Oncol 1999;17:2541-2545.


  • Streit M et al.
    Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy.
    Cancer Res 2002;62:2004-2012.


  • Vu TH et al.
    MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes.
    Cell 1998;93:411-422.


  • Willett CG et al.
    Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Nat Med 2004;10:145-147.


  • Yang JC et al.
    A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
    N Engl J Med 2003;349:427-434.


  • Yip D et al.
    Matrix metalloproteinase inhibitors: applications in oncology.
    Invest New Drugs 1999;17:387-399.


  • Zogakis TG, Libutti SK.
    General aspects of antiangiogenesis and cancer therapy.
    Expert Opin Biol Ther 2001;1:253-275.


  • Zucker S et al.
    Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
    Int J Cancer 1998;75:780-786.


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]